<doc>
  <docmeta id="113hr2315ih">
    <bill congress="113" type="hr" number="2315" version="ih"/>
    <revision size="3479" annotations="0" status="complete" id="4" commit-time="2013-07-09T01:46:58Z" committer="mbohmer" doc="113hr2315ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H89CFEC2CE5F143A28E7B8A826B274450" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 2315 IH: Preserving Access to Orphan Drugs Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-06-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2315</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130611">June 11, 2013</action-date>
			<action-desc>
        <sponsor name-id="G000549">Mr. Gerlach</sponsor> (for
			 himself and <cosponsor name-id="N000015">Mr. Neal</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in
			 addition to the Committee on <committee-name committee-id="HWM00">Ways and
			 Means</committee-name>, for a period to be subsequently determined by the
			 Speaker, in each case for consideration of such provisions as fall within the
			 jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To clarify the orphan drug exception to the annual fee on
		  branded prescription pharmaceutical manufacturers and
		  importers.</official-title>
	</form>
	<legis-body id="H9C95222EF6B746FD8CB6E7E56B532D7C" style="OLC">
		<section id="H5B8AAA03A71E42A486FF44FC4CD05D7E" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Preserving Access to Orphan Drugs Act
			 of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H3DDDDE1133A544F1ABF5DA9089ABEE02" section-type="subsequent-section">
      <enum>2.</enum>
      <header>Clarification of
			 orphan drug exception to annual fee on branded prescription pharmaceutical
			 manufacturers and importers</header>
			<subsection commented="no" id="HDC3B04CE008548C4878F0A6C629126BF">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Patient Protection and Affordable Care Act/s:9008/ss:e/p:3">Paragraph (3) of
			 section 9008(e) of the Patient Protection and Affordable Care Act</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/111/148">Public Law
			 111–148</cato:entity-ref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="H757315418F1C49D5AD40EF3C5B1C03F3" style="OLC">
					<paragraph commented="no" id="H289A0D32ED1A4AED9A465B11C61B7462">
            <enum>(3)</enum>
            <header>Exclusion of
				orphan drug sales</header>
						<subparagraph commented="no" id="H7B5ADACBD2B44DC3ADCAF6EEA5638DA5">
              <enum>(A)</enum>
              <header>In
				general</header>
              <text display-inline="yes-display-inline">The term
				<term>branded prescription drug sales</term> shall not include sales of any
				drug or biological product—</text>
							<clause commented="no" id="H929C01632E0D4F91BD47C62A7BDE0BE7">
                <enum>(i)</enum>
                <text>with respect to
				which a credit was allowed for any taxable year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:45C">section 45C of the
				Internal Revenue Code of 1986</cato:entity-ref>; or</text>
							</clause>
              <clause commented="no" id="H39E06524DC8A432AA49A9D8F5A5D79BC">
                <enum>(ii)</enum>
                <text>which is approved
				or licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug Administration</cato:entity-ref> for marketing solely for one or
				more rare diseases or conditions.</text>
							</clause>
            </subparagraph>
            <subparagraph commented="no" id="H846159FA93FB4FDC9FCBFEB75086D30B">
              <enum>(B)</enum>
              <header>Limitation</header>
              <text>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Patient Protection and Affordable Care Act/s:90008/ss:e/p:3/sp:A" proposed="true">Subparagraph
				(A)</cato:entity-ref> shall not apply with respect to any drug or biological product after the
				date on which the drug or biological product is approved or licensed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for marketing for any indication other than the
				treatment of a rare disease or condition.</text>
						</subparagraph>
            <subparagraph commented="no" id="H37609241177F42CF801F617428392892">
              <enum>(C)</enum>
              <header>Rare disease or
				condition</header>
              <text>In this paragraph, the term <term>rare disease or
				condition</term> has the meaning given such term under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:45C/ss:d/p:1">section 45C(d)(1) of the
				Internal Revenue Code of 1986</cato:entity-ref>, except that in the case of any drug or
				biological product that has not been designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:526">section 526 of the
				Federal Food, Drug, and Cosmetic Act</cato:entity-ref> for a particular indication,
				determinations under such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:45C/ss:d/p:1">section 45C(d)(1)</cato:entity-ref> shall be made on the basis of the
				facts and circumstances as of the date such drug or biological product is
				approved or licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for marketing for the
				treatment of such disease or
				condition.</text>
						</subparagraph>
          </paragraph>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HC5F31F1C3FD540099EF28B8C76626431">
        <enum>(b)</enum>
        <header>Effective
			 date</header>
        <text>The amendment made by this section shall take effect as if
			 included in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Patient Protection and Affordable Care Act/s:9008">section 9008 of the Patient Protection and Affordable Care Act</cato:entity-ref>
			 (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">
              <cato:entity-ref entity-type="public-law" value="public-law/111/148">Public Law 111–148</cato:entity-ref>
            </external-xref>)</cato:entity>.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>